Clinical trials
Phase 3 Thyroid Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 6 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Exelixis | 2 |
| Fudan University | 2 |
| Genzyme, a Sanofi Company | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| Samsung Medical Center | 2 |
| Bayer | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Centre Francois Baclesse | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Eisai Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Neoplasms | 23 |
| Carcinoma, Medullary | 2 |
| Lymphatic Metastasis | 2 |
| Thyroid Cancer, Papillary | 2 |
| Adenocarcinoma, Follicular | 1 |
| Goiter | 1 |
| Head and Neck Neoplasms | 1 |
| Lacrimal Duct Obstruction | 1 |
| Recurrence | 1 |
| Thyroid Carcinoma, Anaplastic | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.